Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central nervous system, conolidine modulates alternate molecular targets. A Science Advances review discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://philipc631unc0.wikitelevisions.com/user